Provided by Tiger Trade Technology Pte. Ltd.

ProShares Pet Care ETF

48.31
+0.29790.62%
Post-market: 48.22-0.0881-0.18%19:30 EDT
Volume:735
Turnover:35.43K
Market Cap:31.40M
PE:- -
High:48.31
Open:48.29
Low:48.22
Close:48.01
52wk High:57.44
52wk Low:45.96
Shares:650.00K
Float Shares:650.00K
Volume Ratio:0.63
T/O Rate:0.11%
Dividend:0.36
Dividend Rate:0.75%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Merck Starts Phase 1 Trial of Oral Peptide Developed With Cyprumed's Technology

MT Newswires Live
·
Sep 29

Scotiabank Adjusts PT on Merck & Co. to $180 From $155, Keeps Sector Outperform Rating

MT Newswires Live
·
Sep 29

Cyprumed : Eligible to Receive up to $493.00m in Milestones from Merck & Co Collaboration

THOMSON REUTERS
·
Sep 29

Merck & Co Inc : Scotiabank Raises Target Price to $180 from $155

THOMSON REUTERS
·
Sep 29

Teva Pharmaceutical's Duvakitug Could be Validated by Merck's Tulisokibart Results, Oppenheimer Says

MT Newswires Live
·
Sep 28

US Drugmakers Turn to China for Licensing Deals

Reuters
·
Sep 28

Merck in License Pact Worth up to $2.13 Billion with SciBrunch Therapeutics

Dow Jones
·
Sep 28

Merck enters global license agreement with SciBrunch Therapeutics for SPR2015

TIPRANKS
·
Sep 28

Merck Enters into Exclusive Global License Agreement with Scibrunch Therapeutics for Spr2015, an Investigational Oral Kras G12d (On) Inhibitor

Reuters
·
Sep 28

Merck & Co - to Record $400 Mln Pre-Tax Charge, $0.13 Per Share, in Q3 2026

THOMSON REUTERS
·
Sep 28

Merck & Co - Deal Includes $400 Mln Upfront, Total Potential Value $2.13 Bln; Deal Closed

THOMSON REUTERS
·
Sep 28

Merck & Co Inc: Under Agreement, Scibrunch Granted Co Exclusive Rights to Develop, Manufacture & Commercialize Spr2015 Worldwide

THOMSON REUTERS
·
Sep 28

Merck's Keytruda Subcutaneous Formulation Approved for Launch in China

Stock News
·
Sep 28

Ingenia Therapeutics Expects USD 5 Million MK-8748 Milestone Payment from Merck Unit Eyebiotech

Reuters
·
Sep 28

Chewy Stock Tumbles as Growth Story Faces Scrutiny

TIPRANKS
·
Sep 26

Ifinatamab Deruxtecan Biologics License Application for Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn

Reuters
·
Sep 26

Merck, Daiichi Sankyo Withdraw US Application for Lung Cancer Drug

Reuters
·
Sep 26

Merck, Daiichi Sankyo voluntarily withdraw BLA for ifinatamab deruxtecan

TIPRANKS
·
Sep 26

Merck & Co - Daiichi Sankyo and Merck Withdraw Bla for Ifinatamab Deruxtecan in Es-Sclc in U.S.

THOMSON REUTERS
·
Sep 26

Merck & Co - Withdrawal Based on FDA Discussions; Phase 2 Data Do not Satisfy Approval Requirements

THOMSON REUTERS
·
Sep 26